AxoGen (NASDAQ:AXGN – Get Free Report) had its target price lifted by research analysts at Leerink Partners from $56.00 to $65.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the medical equipment provider’s stock. Leerink Partners‘s price target points to a potential upside of 16.65% from the stock’s previous close.
AXGN has been the topic of several other reports. Mizuho set a $65.00 target price on shares of AxoGen in a research report on Wednesday, October 28th. Truist Financial increased their target price on shares of AxoGen from $53.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, October 29th. Jefferies Financial Group reiterated a “buy” rating and set a $60.00 price target on shares of AxoGen in a research report on Wednesday, October 28th. Citizens Jmp boosted their price target on AxoGen from $50.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Thursday, July 30th. Finally, Wells Fargo & Company boosted their price target on AxoGen from $48.00 to $56.00 and gave the stock an “overweight” rating in a research note on Thursday, October 29th. Thirteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, AxoGen has an average rating of “Moderate Buy” and an average target price of $58.67.
Read Our Latest Analysis on AxoGen
AxoGen Stock Performance
AxoGen (NASDAQ:AXGN – Get Free Report) last announced its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.08. AxoGen had a negative net margin of 11.96% and a negative return on equity of 5.35%. The business had revenue of $75.83 million during the quarter, compared to the consensus estimate of $73.45 million. Analysts expect that AxoGen will post -0.36 earnings per share for the current fiscal year.
Insider Buying and Selling at AxoGen
In other news, Director Joseph Tyndall sold 3,500 shares of AxoGen stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total transaction of $173,950.00. Following the completion of the transaction, the director owned 10,650 shares of the company’s stock, valued at $529,305. The trade was a 24.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.44% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On AxoGen
A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of AxoGen during the second quarter valued at $204,123,000. Artemis Investment Management LLP increased its position in AxoGen by 27.5% during the 3rd quarter. Artemis Investment Management LLP now owns 1,780,992 shares of the medical equipment provider’s stock worth $74,659,000 after purchasing an additional 384,200 shares in the last quarter. Wellington Management Group LLP increased its position in AxoGen by 44.3% during the 2nd quarter. Wellington Management Group LLP now owns 1,391,654 shares of the medical equipment provider’s stock worth $64,280,000 after purchasing an additional 427,089 shares in the last quarter. Stephens Investment Management Group LLC increased its position in AxoGen by 336.8% during the 3rd quarter. Stephens Investment Management Group LLC now owns 1,130,854 shares of the medical equipment provider’s stock worth $47,405,000 after purchasing an additional 871,949 shares in the last quarter. Finally, Soleus Capital Management L.P. raised its stake in AxoGen by 1,795.3% in the 3rd quarter. Soleus Capital Management L.P. now owns 1,081,000 shares of the medical equipment provider’s stock valued at $45,316,000 after purchasing an additional 1,023,964 shares during the last quarter. 80.29% of the stock is owned by institutional investors and hedge funds.
About AxoGen
AxoGen, Inc. is a medical technology company focused on repairing peripheral nerve injuries—damage to nerves outside the brain and spinal cord. Its products are used by surgeons in procedures intended to restore nerve function and sensation. The company’s offerings include Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves, and Axoguard products designed to protect, connect or cap nerves during repair. Axogen also provides education and support for healthcare professionals who use its nerve-repair solutions.
See Also
- Five stocks we like better than AxoGen
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.
